Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) EBT: 2012-2025

Historic EBT for Veracyte (VCYT) over the last 13 years, with Sep 2025 value amounting to $18.9 million.

  • Veracyte's EBT rose 12.11% to $18.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.0 million, marking a year-over-year increase of 479.51%. This contributed to the annual value of $25.7 million for FY2024, which is 133.60% up from last year.
  • Veracyte's EBT amounted to $18.9 million in Q3 2025, which was up 1,411.12% from $1.2 million recorded in Q2 2025.
  • Veracyte's EBT's 5-year high stood at $18.9 million during Q3 2025, with a 5-year trough of -$45.7 million in Q1 2021.
  • Over the past 3 years, Veracyte's median EBT value was $1.2 million (recorded in 2025), while the average stood at -$2.1 million.
  • In the last 5 years, Veracyte's EBT tumbled by 785.56% in 2023 and then skyrocketed by 489.31% in 2025.
  • Over the past 5 years, Veracyte's EBT (Quarterly) stood at -$11.3 million in 2021, then skyrocketed by 69.59% to -$3.4 million in 2022, then slumped by 785.56% to -$30.5 million in 2023, then surged by 111.30% to $3.4 million in 2024, then rose by 12.11% to $18.9 million in 2025.
  • Its EBT was $18.9 million in Q3 2025, compared to $1.2 million in Q2 2025 and $7.4 million in Q1 2025.